Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide - Seite 2
Anzeige
Contacts:
Media Relations Mai Tran Tel.: + (33) 1 53 77 46 46 mr@sanofi.com |
Investor Relations George Grofik Tel.: + (33) 1 53 77 45 45 ir@sanofi.com |
Global Diabetes Communications Philip McNamara Tel.: +1 908 981 5497 philipmcnamara@sanofi.com |
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire
Lesen Sie auch
HUG#2036140
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
1 im Artikel enthaltener WertIm Artikel enthaltene Werte